

Serial No. 10/070,084  
Docket No. PU3517USw  
Reply to Office Action of October 23, 2006

RECEIVED  
CENTRAL FAX CENTER

FEB 23 2007

### Remarks

Applicants note with appreciation the allowance of Claims 2-3, 5, 9, 13, 18-20, 23, 25, 28, 34-36, 40, 45-47, 49, 55, 58-62, 65, and 71. Claims 2-3, 5-7, 9, 13, 18-20, 23, 25, 28, 34-36, 40, 43-47, 49, 55, 58-63, 65, 67-69, and 71 are pending. Claims 4, 10-11, 26, 48, 54, 56, 64, 66, 70 and 72 have been canceled from the present application without prejudice to the re-filing of the claims in a continuation application. Claims 6, 7, and 43 are currently amended. Support for the amendments to claim 6 can be found in the specification at page 27, lines 9-12. Claims 7 and 43 depend from claim 6 and have been amended accordingly. No new matter is presented by way of these amendments.

Claims 4, 6, 10, 11, 48, 54, 63-64, 66-70, and 72 stand rejected under 35 USC 103(a) as being unpatentable over Wyatt et al. (J. Med. Chem. 1995). With respect to claims 4, 10, 11, 48, 54, 56, 64, 66, 70 and 72, the rejection is now moot in light of the cancellation of these claims. With respect to claims 6, 63, and 67-69, the Applicants respectfully disagree with this rejection.

Claim 6 has been amended to reflect that  $R^4$  is  $C_{6-14}$ aryl substituted with  $C_{1-8}$ alkyl and at least one of hydroxy, halogen,  $-CF_3$ ,  $C_{1-8}$ alkyl, hydroxy $C_{1-8}$ alkyl,  $-CN$ ,  $-NO_2$ ,  $C_{1-8}$ alkylamino, heterocycle $C_{1-8}$ alkyl,  $-C(O)NH_2$ ,  $-S(O)R^7$ ,  $-S(O)_2R^7$ ,  $-C(O)R^7$ ,  $-NS(O)_2R^7$ ,  $-S(O)_2NR^8R^9$ ,  $-S(O)_2NHR^{11}$ ,  $-S(O)_2R^{11}$ ,  $-S(O)_2NR^7COR^{11}$ ,  $-S(O)_2NHCOR^{11}$ ,  $-S(O)_2[COR^{11}]_n$  wherein  $n$  is 1,  $-OR^{11}$ ,  $-OR^{11}OR^{11}$ ,  $-C(O)R^{11}$ ,  $-C(O)NR^{11}$ ,  $-C(O)OR^{11}$ ,  $-NR^{11}$ ,  $-NC(O)R^{11}$ , heterocycle $C_2-6$ alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo,  $C_{1-8}$ alkyl, and  $C(O)OR^{11}$ , and  $C_{1-8}$ alkyl which may be optionally substituted with one or more substituents selected from the group consisting of  $-CN$  and heterocycle, optionally substituted with  $-C(O)R^{11}$ .

Wyatt does not teach or suggest an alkyl-substituted aryl, and furthermore, Wyatt does not teach or suggest additional substitutions on the specified aryl. One of ordinary skill in the art would not be motivated to take the unsubstituted aryl of Wyatt and place an alkyl and at least one additional substituent on that aryl.


Applicants respectfully request reconsideration and withdrawal of this rejection.

In view of the amendments and foregoing discussion, it is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Serial No. 10/070,084  
Docket No. PU3517USw  
Reply to Office Action of October 23, 2006

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,




Kimberly H. Parker  
Attorney for Applicant  
Registration No. 47,843

Date: Feb 23, 2007

Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Tel: (919) 483-8406  
Fax: (919) 483-7988

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office at (571) 273-8300 on February 23, 2007.

  
Rebecca Kerney